# Longitudinal Evaluation and Real-world Evidence of NT201

> **NCT05222607** · — · TERMINATED · sponsor: **Merz North America, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face

## Interventions

- **DRUG:** IncobotulinumtoxinA

## Key facts

- **NCT ID:** NCT05222607
- **Lead sponsor:** Merz North America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-10
- **Primary completion:** 2023-05-18
- **Final completion:** 2023-05-18
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Corporate Management Decision
- **Last updated:** 2023-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05222607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05222607, "Longitudinal Evaluation and Real-world Evidence of NT201". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05222607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*